Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GPhA Reorganization Starts With Sales Pitch At CEO Summit

This article was originally published in The Pink Sheet Daily

Executive Summary

Board of directors approves transition plan, but search for a new head of the association will await a better estimate of revenue.

You may also be interested in...



GPhA Enters 2011 Bigger And Stronger, But With A Broader Fight On Its Hands

The Generic Pharmaceutical Association is pretty fond of Florida. The group has held its annual meeting in the state almost every year since the association was formed. But regardless of the weather or the hotel amenities, when GPhA convenes in Orlando next month, its members will be slightly disappointed in the venue: Florida is below the national average in the generic utilization rate for its Medicaid program.

GPhA Enters 2011 Bigger And Stronger, But With A Broader Fight On Its Hands

The Generic Pharmaceutical Association is pretty fond of Florida. The group has held its annual meeting in the state almost every year since the association was formed. But regardless of the weather or the hotel amenities, when GPhA convenes in Orlando next month, its members will be slightly disappointed in the venue: Florida is below the national average in the generic utilization rate for its Medicaid program.

ANDA User Fee Negotiations: A Big-Firm Coalition Tackles The Big Backlog

FDA has long negotiated its brand user fee program with two distinct but closely aligned industry groups: the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization. Now the agency will be using those same discussion techniques as it develops the generic drug user fee program.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel